{"nctId":"NCT00089674","briefTitle":"AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer","startDateStruct":{"date":"2004-08-01","type":"ACTUAL"},"conditions":["Prostate Cancer"],"count":1468,"armGroups":[{"label":"AMG 162","type":"EXPERIMENTAL","interventionNames":["Drug: AMG 162"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"AMG 162","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Other criteria also apply","healthyVolunteers":false,"sex":"MALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 24","description":"Lumbar Spine Bone Mineral Density Percent Chnage From Baseline at Month 24 Assessed by Dual Energy X-Ray Absorptiometry.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1","spread":null},{"groupId":"OG001","value":"5.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 24","description":"Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 24 Assessed by Dual Energy X-Ray Absorptiometry.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.5","spread":null},{"groupId":"OG001","value":"2.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Total Hip Bone Mineral Density Percent Change From Baseline at Month 24","description":"Total Hip Bone Mineral Density Percent Change From Baseline at Month 24 Assessed by Dual Energy X-Ray Absorptiometry.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2","spread":null},{"groupId":"OG001","value":"2.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 36","description":"Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 36 Assessed by Dual Energy X-Ray Absorptiometry.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.2","spread":null},{"groupId":"OG001","value":"6.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 36","description":"Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 36 Assessed by Dual Energy X-Ray Absorptiometry.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.8","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Total Hip Bone Mineral Density Percent Change From Baseline at Month 36","description":"Total Hip Bone Mineral Density Percent Change From Baseline at Month 36 Assessed by Dual Energy X-Ray Absorptiometry.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.6","spread":null},{"groupId":"OG001","value":"3.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Any Fracture Through Month 36","description":"Any fracture includes osteroporotic fractures at any site excluding skull, facial, mandible, metacarpals, finger phalanges, and toe phalanges.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53","spread":null},{"groupId":"OG001","value":"38","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With a New Vertebral Fracture Through Month 36","description":"New Vertebral Fracture Assessed by Lateral Spine X-ray using Genant Semiquantitative Scoring Method excluding any symptomatic new vertebral fracture associated with high trauma severity or a pathologic fracture.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to First Clinical Fracture Through Month 36","description":"A clinical fracture was defined as any nonvertebral fracture or clinically evident fracture at the cervical vertebrae, thoracic vertebrae, and lumbar vertebrae that was associated with signs and/or symptoms indicative of a fracture. Fractures associated with high trauma severity and pathologic (ie, metastatic) fractures were excluded. Since the median time was not reached, time to first clinical fracture is represented by the Kaplan-Meier estimate of the percentage of participants with a clinical fracture.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.2","spread":null},{"groupId":"OG001","value":"4.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Any Fracture Through Month 24","description":"Any fracture includes osteroporotic fractures at any site excluding skull, facial, mandible, metacarpals, finger phalanges, and toe phalanges.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45","spread":null},{"groupId":"OG001","value":"32","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":222,"n":725},"commonTop":["Arthralgia","Back pain","Constipation","Pain in extremity","Hypertension"]}}}